Somewhat Positive Press Coverage Somewhat Unlikely to Impact Dicerna Pharmaceuticals (DRNA) Stock Price

Media stories about Dicerna Pharmaceuticals (NASDAQ:DRNA) have been trending somewhat positive recently, according to Accern Sentiment Analysis. The research firm scores the sentiment of media coverage by analyzing more than twenty million blog and news sources in real time. Accern ranks coverage of companies on a scale of -1 to 1, with scores nearest to one being the most favorable. Dicerna Pharmaceuticals earned a news sentiment score of 0.23 on Accern’s scale. Accern also assigned media stories about the biopharmaceutical company an impact score of 46.6188098327956 out of 100, indicating that recent media coverage is somewhat unlikely to have an effect on the company’s share price in the near future.

These are some of the media stories that may have impacted Accern’s scoring:

How to Become a New Pot Stock Millionaire

DRNA has been the subject of several research reports. ValuEngine upgraded Dicerna Pharmaceuticals from a “sell” rating to a “hold” rating in a research note on Friday, February 2nd. B. Riley began coverage on Dicerna Pharmaceuticals in a research note on Wednesday, March 28th. They issued a “neutral” rating and a $10.00 target price for the company. BidaskClub upgraded Dicerna Pharmaceuticals from a “hold” rating to a “buy” rating in a research report on Thursday, January 25th. Zacks Investment Research downgraded Dicerna Pharmaceuticals from a “hold” rating to a “sell” rating in a research report on Thursday, February 1st. Finally, SunTrust Banks assumed coverage on Dicerna Pharmaceuticals in a research report on Monday, February 5th. They set a “buy” rating and a $13.00 price target for the company. One analyst has rated the stock with a sell rating, five have assigned a hold rating and four have given a buy rating to the stock. The stock presently has an average rating of “Hold” and a consensus target price of $12.04.

Dicerna Pharmaceuticals stock traded up $0.11 during trading hours on Thursday, reaching $9.69. The company had a trading volume of 460,914 shares, compared to its average volume of 448,716. The stock has a market capitalization of $473.15, a P/E ratio of -2.65 and a beta of 2.34. Dicerna Pharmaceuticals has a 12-month low of $2.69 and a 12-month high of $15.00.

Dicerna Pharmaceuticals (NASDAQ:DRNA) last issued its quarterly earnings data on Thursday, March 8th. The biopharmaceutical company reported ($0.90) earnings per share for the quarter, missing the Zacks’ consensus estimate of ($0.65) by ($0.25). The business had revenue of $1.40 million during the quarter, compared to the consensus estimate of $1.45 million. Dicerna Pharmaceuticals had a negative return on equity of 171.81% and a negative net margin of 2,637.15%. The company’s quarterly revenue was up 976.9% on a year-over-year basis. sell-side analysts forecast that Dicerna Pharmaceuticals will post -1.15 earnings per share for the current year.

ILLEGAL ACTIVITY WARNING: This article was first posted by BBNS and is the sole property of of BBNS. If you are reading this article on another domain, it was stolen and reposted in violation of US and international copyright & trademark law. The legal version of this article can be read at https://baseballnewssource.com/2018/04/05/dicerna-pharmaceuticals-drna-receives-daily-news-impact-rating-of-0-23/2027818.html.

About Dicerna Pharmaceuticals

Dicerna Pharmaceuticals, Inc is a ribonucleic acid (RNA) interference-based biopharmaceutical company. The Company operates in the segment of discovery, research and development of treatments based on its RNA interference (RNAi) technology platform. The Company is focused on the discovery and development of treatments for rare inherited diseases involving the liver and for cancers that are genetically defined.

Insider Buying and Selling by Quarter for Dicerna Pharmaceuticals (NASDAQ:DRNA)

Receive News & Ratings for Dicerna Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Dicerna Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.

 


Latest News

Almora Jr. and Baez Could Become Cubs new One-Two Tandem
Almora Jr. and Baez Could Become Cubs new One-Two Tandem
Red Sox Tie Record for Best Start After 17 Games
Red Sox Tie Record for Best Start After 17 Games
Bryce Harper Hits 406-Foot Home Run While Breaking His Bat
Bryce Harper Hits 406-Foot Home Run While Breaking His Bat
Rick Porcello’s Strong Start Gives Boost to Red Sox
Rick Porcello’s Strong Start Gives Boost to Red Sox
Two Bench Clearing Incidents Revive Red Sox-Yankees Rivalry
Two Bench Clearing Incidents Revive Red Sox-Yankees Rivalry
Xander Bogaerts Goes on Red Sox DL
Xander Bogaerts Goes on Red Sox DL


Leave a Reply

 
© 2006-2018 BBNS.